

BRETT GUTHRIE, KENTUCKY  
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY  
RANKING MEMBER

ONE HUNDRED NINETEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-3641  
Minority (202) 225-2927

April 20, 2026

John Murphy  
President and CEO  
Association for Accessible Medicines  
601 New Jersey Ave NW  
Suite 850  
Washington DC 20001

Dear Mr. Murphy:


Thank you for appearing before the Subcommittee on Health on Wednesday, February 11, 2026, to testify at the hearing entitled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain.”

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Monday, May 4, 2026. Your responses should be mailed to Annabelle Huffman, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to [Annabelle.Huffman@mail.house.gov](mailto:Annabelle.Huffman@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



H. Morgan Griffith  
Chairman  
Subcommittee on Health

cc: Diana DeGette, Ranking Member, Subcommittee on Health  
Attachment

## **Attachment — Additional Questions for the Record**

### **The H. Morgan Griffith (R-VA)**

1. It is often a race to the lowest price with generic medicines, which causes companies to pull out of the market. We all want lower prices, but we need to find better ways to incentivize development and competition. When it comes to generic drugs, how can we shift the focus toward quality and a healthy market to foster competition?
2. Generic medications account for 90 percent of the drugs prescribed in America, but their production has become increasingly consolidated. What percentage of generic medications have three or fewer manufacturers and what percentage of generic medications have only one manufacturer?